Dr Reddy’s International Business Makes Up For Domestic Decline
Company Begins To Integrate Wockhardt Business Following Acquisition
Executive Summary
Dr Reddy’s saw growth particularly in Europe, North America and international markets in the firm’s financial first quarter ended June 2020. However, the company’s domestic business saw a decline of a due to the impact of COVID-19.
You may also be interested in...
Generics Industry Counts Cost Of Stormy Second Quarter
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
Dr Reddy’s Revises Wockhardt Terms In Light Of COVID-19 Slump
Dr Reddy’s has completed its deal for Wockhardt’s branded generics business. However, the two companies have renegotiated the financial terms of the deal following the impact of the COVID-19 pandemic on Wockhardt’s business.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.